The 4th PVRI Annual Drug Discovery & Development Symposium for Pulmonary Hypertension was a great success based on the very positive reviews of those who attended. This year we had more representation from industry than in years past. As has been the case in prior years, the format of a 20-minute presentation followed by 40 minutes of discussion resulted in spirited and highly informative interactions among the attendees. This year there were 4 presentations of drugs under development that had anti-inflammatory properties, reflecting a change in the industry approach to treating pulmonary vascular disease away from vasodilators and towards addressing underlying mechanisms of disease. Reviews of the potential for drugs targeting serotonin, tyrosine kinases, and mRNAs were all thought provoking. Experiences of a multimodality approach to CTEPH utilising surgical pulmonary endarterectomy, pulmonary balloon angioplasty, and riociguat in the same patients suggest this is a field that will be evolving in the near future.
This year also saw the creation of the PVRI Pharma Task Force as a collaborative effort between academia, regulatory, and industry to work together 'to create and provide a platform for early and continuous dialogue on innovative clinical and regulatory development strategies' in the area of pulmonary vascular disease. This effort was well received by everyone in attendance, and will be an ongoing feature of future symposia.